T2DM: low HbA1c levels tied to increased hypoglycaemia risk

  • Malawana M & al.
  • JRSM Open
  • 1 Jul 2018

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Risk of experiencing episodes of clinical hypoglycaemia was significantly higher among patients with type 2 diabetes (T2DM) on sulphonylureas or insulin with low level of HbA1c (
  • Hypoglycaemia and mortality risk were higher among patients receiving insulin compared with sulphonylureas.

Why this matters

  • Hypoglycaemia is a major side effect of intensive glucose-lowering treatment and is commonly associated with falls, fractures, and road traffic accidents.
  • Findings support the need for reviewing glycaemic targets and the intensities of treatment in patients with low HbA1c prescribed insulins or sulphonylureas to reduce hypoglycaemia risk.

Study design

  • Retrospective cohort study of 18,628 patients (insulin, n=6788; sulphonylureas, n=11,840) with T2DM.
  • Funding: Queen Mary University of London.

Key results

  • 1315 patients (insulin, n=675; sulphonylureas, n=640) experienced an episode of hypoglycaemia and 1037 deaths were recorded.
  • Hypoglycaemia was more common among patients with a HbA1c level below 53 mmol/mol in the insulin (aHR, 1.26; 95% CI, 0.97-1.63) and sulphonylurea group (aHR, 1.54; 95% CI, 1.27-1.87) vs patients with an elevated level of HbA1c.
  • All-cause mortality was higher among patients with low HbA1c in the insulin (aHR, 1.54; 95% CI, 1.15-2.07) and sulphonylurea groups (aHR, 1.42; 95% CI, 1.11-1.81).
  • Patients receiving insulin and having a higher level of HbA1c (≥86 mmol/mol) showed an increased risk for hypoglycaemia (HR, 2.22; 95% CI, 1.51-3.26) vs sulphonylurea group.

Limitations

  • Only a single baseline HbA1c measurement was included.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit